Skip to main content
SpringerLink
Log in

Ist Sacubitril/Valsartan bei fortgeschrittener Nierenerkrankung und Dialysepflichtigkeit eine gute Option?

Is sacubitril/valsartan a good option for advanced kidney disease and dialysis dependency?

  • Arzneimitteltherapie
  • Published:
Die Nephrologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. McCullough PA, Roberts WC (2016) Influence of chronic renal failure on cardiac structure. J Am Coll Cardiol 67:1183–1185

    Article  PubMed  Google Scholar 

  2. Niu CY et al (2022) Sacubitril/Valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc 11(18):e026407

  3. Haynes R et al (2020) Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant 35:558–564

    Article  CAS  PubMed  Google Scholar 

  4. McAlister FA et al (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 5:309–314

    Article  PubMed  Google Scholar 

  5. Ahmed A, Campbell RC (2008) Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 4:387–399

    Article  PubMed  PubMed Central  Google Scholar 

  6. McMurray JJ et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure (Paradigm). N Engl J Med 371:993–1004

    Article  PubMed  Google Scholar 

  7. McDonagh TA et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726

    Article  CAS  PubMed  Google Scholar 

  8. Heidenreich PA et al (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail 28:e1–e167

    Article  Google Scholar 

  9. Greene SJ et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72:351–366

    Article  PubMed  Google Scholar 

  10. Huitema AA et al (2020) Optimal usage of sacubitril/valsartan for the treatment of heart failure: the importance of optimizing heart failure care in Canada. CJC Open 2:321–327

    Article  PubMed  PubMed Central  Google Scholar 

  11. Solomon SD et al (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

    Article  CAS  PubMed  Google Scholar 

  12. Volpe M, Carnovali M, Mastromarino V (2016) The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin Sci 130:57–77

    Article  CAS  Google Scholar 

  13. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G (2017) Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet 56:1461–1478

    Article  CAS  PubMed  Google Scholar 

  14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf

  15. https://www.ema.europa.eu/en/documents/overview/entresto-epar-summary-public_en.pdf

  16. Damman K et al (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6:489–498

    Article  PubMed  Google Scholar 

  17. Benigni A et al (2004) Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 66:1959–1965

    Article  CAS  PubMed  Google Scholar 

  18. Davis BJ et al (2003) Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 46:961–971

    Article  CAS  PubMed  Google Scholar 

  19. Taal MW et al (2001) Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051–2059

    Article  CAS  PubMed  Google Scholar 

  20. Cao Z et al (2001) Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60:715–721

    Article  CAS  PubMed  Google Scholar 

  21. Spannella F, Giulietti F, Filipponi A, Sarzani R (2020) Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail 7:3487–3496

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zhou W et al (2023) The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 56(1):181–190

    Article  PubMed  Google Scholar 

  23. Haynes R et al (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial. Circulation 138:1505–1514

    Article  CAS  PubMed  Google Scholar 

  24. Jia R et al (2022) Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. Eur J Pharmacol 928:175053

    Article  CAS  PubMed  Google Scholar 

  25. Vollmer Barbosa C, Lang H, Melk A, Schmidt BMW (2022) Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis. Nephrol Dial Transplant 37:2418–2428

    Article  PubMed  Google Scholar 

  26. Charkviani M, Krisanapan P, Thongprayoon C, Craici IM, Cheungpasitporn W (2024) Systematic review of cardiovascular benefits and safety of sacubitril-valsartan in end-stage kidney disease. Kidney Int Rep 9:39–51

    Article  PubMed  Google Scholar 

  27. Hsiao F‑C, Lin C‑P, Yu C‑C, Tung Y‑C, Chu P‑H (2022) Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med 9:794707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. https://www.novartis.com/at-de/sites/novartis_at/files/FI_Entresto.pdf

  29. Guo Y et al (2022) Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF. Front Cardiovasc Med 9:55780

    Article  Google Scholar 

  30. Feng Z et al (2021) Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in maintenance hemodialysis patients with heart failure. Blood Purif 51:270–279

    Article  PubMed  Google Scholar 

  31. Fu S et al (2021) Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis. Front Med 8:657067

    Article  Google Scholar 

  32. Lee S et al (2020) Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail 7:1125–1129

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ma JW, Ren LL, Huang JC (2023) Efficacy of sacubitril/valsartan in peritoneal dialysis patients with HFpEF and its effect on residual renal function. Zhonghua Yi Xue Za Zhi 103:117–124

    CAS  PubMed  Google Scholar 

  34. Wang B et al (2022) Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients. J of Clinical Hypertension 24:300–308

    Article  CAS  Google Scholar 

  35. Lihua W, Cheng L, Chen H (2021) Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a single center. Iran J Kidney Dis 15:288–299

    PubMed  Google Scholar 

  36. Martínez-Esteban MD et al (2022) Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice. BMC Nephrol 23:293

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Clara Vollmer Barbosa

Authors
  1. Clara Vollmer Barbosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clara Vollmer Barbosa.

Ethics declarations

Interessenkonflikt

C. Vollmer Barbosa gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Kirsten de Groot, Offenbach

Roland Schmitt, Hannover

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vollmer Barbosa, C. Ist Sacubitril/Valsartan bei fortgeschrittener Nierenerkrankung und Dialysepflichtigkeit eine gute Option?. Nephrologie (2024). https://doi.org/10.1007/s11560-024-00731-4

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11560-024-00731-4

Search

Navigation